Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncotelic TherapeuticsOTLC -2.14% Receivables Turnover is 121.48 as of Jun. 2026. The stock has 3 warning signs investors should review. Among 853 Biotechnology companies, Oncotelic Therapeutics ranks better than 88.39% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Oncotelic Therapeutics's Revenue for the
three
months ended in Jun. 2026 was $0.25 Mil. Oncotelic Therapeutics's average Accounts Receivable for the
three
months ended in Jun. 2026 was $0.00 Mil.
Hence, Oncotelic Therapeutics's Receivables Turnover for the
three
months ended in Jun. 2026 was 121.48.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Oncotelic Therapeutics Receivables Turnover Related Terms
Oncotelic Therapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Oncotelic Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OTLC vs DARE, PASG, INTS: Receivables Turnover Comparison
For the Biotechnology subindustry, Oncotelic Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncotelic Therapeutics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncotelic Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Oncotelic Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncotelic Therapeutics (OTLC) has a Receivables Turnover of 121.48 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Oncotelic Therapeutics and its competitors. According to the industry distribution chart, Oncotelic Therapeutics ranks #99 out of 853 companies in the Biotechnology industry, placing it in the top 11.6%.
Is Oncotelic Therapeutics' Receivables Turnover too high?
Oncotelic Therapeutics' current Receivables Turnover is 121.48. The Biotechnology industry median Receivables Turnover is 5.28. Oncotelic Therapeutics' value of 121.48 is 2200.8% above this industry median. Based on the distribution chart, Oncotelic Therapeutics ranks #99 out of 853 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Oncotelic Therapeutics' Receivables Turnover compare to DARE and PASG?
According to the Biotechnology industry distribution chart, Oncotelic Therapeutics ranks #99 out of 853 companies for Receivables Turnover. This places Oncotelic Therapeutics in the top 12% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.28. Oncotelic Therapeutics' value of 121.48 is 2200.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncotelic Therapeutics's current Receivables Turnover of 121.48 is 2200.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Oncotelic Therapeutics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncotelic Therapeutics's current Receivables Turnover is 121.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncotelic Therapeutics stock overvalued right now?
Oncotelic Therapeutics (OTLC) has a current Receivables Turnover of 121.48. The current Receivables Turnover is 121.48 and 2200.8% above the Biotechnology industry median of 5.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Oncotelic Therapeutics (OTLC), the current Receivables Turnover is 121.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. OT-101 is its flagship immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under the pipeline are Artemisinin, CA4P, AL-101, and Oxi4503.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTLC has been successfully added to your 
